Media Center
Press Releases
2022
Astex Co-founder and CEO Harren Jhoti Awarded OBE in the King’s New Year Honours
31 December 2022/by webadminTaiho Oncology and Astex Pharmaceuticals Present Overall Survival Data for Oral Decitabine and Cedazuridine (INQOVI®, ASTX727) in Patients With MDS and CMML Harboring TP53 Mutations at 64th ASH Annual Meeting
12 December 2022/by Peggy BickertonEuropean Medicines Agency commences review of oral fixed-dose combination of decitabine and cedazuridine for the treatment of adults with acute myeloid leukemia
22 August 2022/by Peggy BickertonAstex announces that the phase 3 ASCERTAIN – acute myeloid leukemia (AML) clinical study of oral hypomethylating agent decitabine and cedazuridine fixed-dose combination (ASTX727 or DEC-C) met the trial’s primary endpoint
12 May 2022/by Peggy BickertonOral decitabine and cedazuridine (ASTX727) granted Orphan Drug Designation (ODD) by the European Commission for the treatment of Acute Myeloid Leukemia (AML)
6 January 2022/by Peggy Bickerton2021
Astex Pharmaceuticals Presents Overall Survival Data From ASCERTAIN Phase 3 Study of Oral Hypomethylating Agent INQOVI® (decitabine and cedazuridine) in MDS and CMML at International Congress on Myelodysplastic Syndromes
23 September 2021/by Peggy BickertonNCCN Announces Projects to Study Oral Decitabine and Cedazuridine in Collaboration with Taiho Oncology
14 April 2021/by Peggy Bickerton2020
Astex Pharmaceuticals expands clinical evaluation of oral decitabine and cedazuridine tablets through new Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI)
28 October 2020/by Peggy BickertonAstex and Otsuka announce results of phase 3 ASTRAL-2 and ASTRAL-3 studies of guadecitabine (SGI-110) in patients with previously treated acute myeloid leukemia (AML) and myelodysplastic syndromes or chronic myelomonocytic leukemia (MDS/CMML)
14 October 2020/by Peggy BickertonAstex Pharmaceuticals and MD Anderson Announce Strategic Collaboration to Accelerate Clinical Evaluation of Therapies for Patients with Leukemia
8 September 2020/by Peggy BickertonAstex Pharmaceuticals Announces That Tolinapant (ASTX660), a Novel Antagonist of Cellular and X-linked Inhibitors of Apoptosis Proteins, Has Been Granted Orphan Drug Designation for the Treatment of T-cell Lymphomas by the US FDA
31 August 2020/by Peggy BickertonAstex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health Canada approval of INQOVI® (decitabine and cedazuridine) tablets.
7 July 2020/by Renee HansenAstex Pharmaceuticals announces U.S. Food and Drug Administration (FDA) acceptance for review of an NDA for the combination oral hypomethylating agent cedazuridine and decitabine (ASTX727 or oral C-DEC), for the treatment of MDS and CMML
11 February 2020/by Peggy Bickerton2019
Astex Pharmaceuticals presents topline data from the ASCERTAIN phase 3 study of its novel, oral hypomethylating agent cedazuridine and decitabine (ASTX727) in MDS and CMML at the American Society of Hematology Meeting in Orlando, FL.
9 December 2019/by Peggy BickertonTaiho Oncology Announces Agreement with Otsuka to Commercialize Astex Pharmaceuticals’ Drug Candidates
7 June 2019/by Peggy BickertonBritish Company Behind Groundbreaking Breast Cancer Treatment
7 June 2019/by webadminAstex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval
12 April 2019/by webadmin2018
Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy
30 July 2018/by Renee HansenAstex’s Harren Jhoti Made Fellow of the Royal Society
9 May 2018/by webadminAstex Continues to Deliver in Oncology as Erdafitinib, a Potential New Treatment for Metastatic Urothelial Cancer, Receives US FDA Breakthrough Therapy Designation
15 March 2018/by webadminHarren Jhoti Receives Lifetime Achievement Award from the UK BioIndustry Association
26 January 2018/by webadminOtsuka Signs Statement of Support for Women’s Empowerment Principles
19 January 2018/by Peggy Bickerton2017
2022
- Astex Co-founder and CEO Harren Jhoti Awarded OBE in the King’s New Year Honours 31 December 2022
- Taiho Oncology and Astex Pharmaceuticals Present Overall Survival Data for Oral Decitabine and Cedazuridine (INQOVI®, ASTX727) in Patients With MDS and CMML Harboring TP53 Mutations at 64th ASH Annual Meeting 12 December 2022
- European Medicines Agency commences review of oral fixed-dose combination of decitabine and cedazuridine for the treatment of adults with acute myeloid leukemia 22 August 2022
- Astex announces that the phase 3 ASCERTAIN – acute myeloid leukemia (AML) clinical study of oral hypomethylating agent decitabine and cedazuridine fixed-dose combination (ASTX727 or DEC-C) met the trial’s primary endpoint 12 May 2022
- Oral decitabine and cedazuridine (ASTX727) granted Orphan Drug Designation (ODD) by the European Commission for the treatment of Acute Myeloid Leukemia (AML) 6 January 2022
2021
- Astex Pharmaceuticals Presents Overall Survival Data From ASCERTAIN Phase 3 Study of Oral Hypomethylating Agent INQOVI® (decitabine and cedazuridine) in MDS and CMML at International Congress on Myelodysplastic Syndromes 23 September 2021
- NCCN Announces Projects to Study Oral Decitabine and Cedazuridine in Collaboration with Taiho Oncology 14 April 2021
2019
- Astex Pharmaceuticals presents topline data from the ASCERTAIN phase 3 study of its novel, oral hypomethylating agent cedazuridine and decitabine (ASTX727) in MDS and CMML at the American Society of Hematology Meeting in Orlando, FL. 9 December 2019
- Taiho Oncology Announces Agreement with Otsuka to Commercialize Astex Pharmaceuticals’ Drug Candidates 7 June 2019
- British Company Behind Groundbreaking Breast Cancer Treatment 7 June 2019
- Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval 12 April 2019
2018
- Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy 30 July 2018
- Astex’s Harren Jhoti Made Fellow of the Royal Society 9 May 2018
- Astex Continues to Deliver in Oncology as Erdafitinib, a Potential New Treatment for Metastatic Urothelial Cancer, Receives US FDA Breakthrough Therapy Designation 15 March 2018
- Harren Jhoti Receives Lifetime Achievement Award from the UK BioIndustry Association 26 January 2018
- Otsuka Signs Statement of Support for Women’s Empowerment Principles 19 January 2018
2016
- Astex to Showcase Its Next-Generation Hypomethylating Agents Being Developed for Treatment of AML/MDS at the 2016 Annual Meeting of the American Society of Hematology 29 November 2016
- Astex Joins the Dementia Discovery Fund as a Strategic Investor 21 November 2016
- Astex Achieves Milestone on US FDA Filing of New Drug Application (NDA) for LEE011 (ribociclib) plus letrozole as a first-line treatment for HR+/HER2- Advanced Breast Cancer 1 November 2016
- Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investigational Compound for Advanced Breast Cancer in Development by Major Pharmaceutical Company under a Research Collaboration with Otsuka’s Subsidiary Astex Pharmaceuticals 20 October 2016
- Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia 19 April 2016
Selected past releases are archived for your reference.